Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
27 févr. 2025 09h00 HE
|
Amarin Corporation plc
-- Peer-Reviewed Paper Indicates Icosapent Ethyl (IPE) Reduced Composite Cardiovascular Endpoint Events Regardless of Baseline LDL-C Levels; Significantly Reduced Events by 34% Among Patients with...
Amarin Receives National Reimbursement for VAZKEPA® in Austria
25 févr. 2025 08h00 HE
|
Amarin Corporation plc
-- Austrian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Risk of Cardiovascular Events in Eligible Patients -- -- Effective 1 April 2025,...
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
19 févr. 2025 08h30 HE
|
Amarin Corporation plc
DUBLIN and BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and...
Amarin Receives National Reimbursement for VAZKEPA® in Italy
16 déc. 2024 07h00 HE
|
Amarin Corporation plc
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 -- -- Italy is the Third EU5 Market to Grant...
Amarin Appoints Peter Fishman Chief Financial Officer
13 déc. 2024 09h00 HE
|
Amarin Corporation plc
DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company,...
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
11 nov. 2024 08h00 HE
|
Amarin Corporation plc
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark...
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
30 oct. 2024 16h05 HE
|
Amarin Corporation plc
-- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance ---- Total Net Revenue of $42 Million Represents Continued Source of Cash from the U.S., RoW...
Amarin Announces Two Upcoming Investor Events
01 oct. 2024 08h00 HE
|
Amarin Corporation plc
-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual Analyst & Investor Day Thursday, November 14 -- DUBLIN and BRIDGEWATER, N.J., Oct. ...
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
09 sept. 2024 07h30 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of...
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
22 août 2024 08h30 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT®...